ReviewInflammopharmacology2022
Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?
Review in Inflammopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Repurposing doxycycline as an adjunct to sitagliptin in type 2 diabetes mellitus: a randomized controlled study on glycemic, inflammatory, and cardiometabolic outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2026Trial
- Multifunctional bioactivity of eco-friendly Penicillium gladioli extract against Toxoplasma gondii and Pseudomonas aeruginosa.Scientific reports · 2025Article
- Employing diclofenac sodium as a novel therapeutic frontier for Staphylococcus epidermidis infections.Scientific reports · 2025Article
- Unveiling the antibacterial action of ambroxol against Staphylococcus aureus bacteria: in vitro, in vivo, and in silico investigation.BMC microbiology · 2024Article
- Arthrospira maxima and biosynthesized zinc oxide nanoparticles as antibacterials against carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii: a review article.Microbial cell factories · 2024Review
- Potential Surviving Effect ofAntibiotics (Basel, Switzerland) · 2024Article
- Irisin/PGC-1α/FNDC5 pathway in Parkinson's disease: truth under the throes.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit.European journal of medical research · 2024Review
- The Potential Effect of Dapsone on the Inflammatory Reactions in COVID-19: Staggering View.Combinatorial chemistry & high throughput screening · 2024Review
- VEGFR and DPP-IV as Markers of Severe COVID-19 and Predictors of ICU Admission.International journal of molecular sciences · 2023Article
- SARS-CoV-2 infection and dysregulation of nuclear factor erythroid-2-related factor 2 (Nrf2) pathway.Cell stress & chaperones · 2023Review
- Effects of dipeptidyl peptidase 4 inhibition on the endothelial control of the vascular tone.American journal of physiology. Cell physiology · 2023Review
- Screening compounds for treating the diabetes and COVID-19 from Miao medicine by molecular docking and bioinformatics.Arabian journal of chemistry · 2023Article
- The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer's diseases.Diabetology & metabolic syndrome · 2023Review
- Cholinergic dysfunction in COVID-19: frantic search and hoping for the best.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Effect of DPP4/CD26 expression on SARS‑CoV‑2 susceptibility, immune response, adenosine (derivatives mInternational journal of oncology · 2023Article
- SIRT1 pathway in Parkinson's disease: a faraway snapshot but so close.Inflammopharmacology · 2023Review
- The Potential Nexus between Helminths and SARS-CoV-2 Infection: A Literature Review.Journal of immunology research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (Covid-19) is caused by severe acute respiratory syndrome type 2 (SARS-CoV-2). Covid-19 is characterized by hyperinflammation, oxidative stress, and multi-organ injury (MOI) such as acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Covid-19 is mainly presented with respiratory manifestations; however, extra-pulmonary manifestations may also occur. Extra-pulmonary manifestations of Covid-19 are numerous including: neurological, cardiovascular, renal, endocrine, and hematological complications. Notably, a cluster of differentiation 26 (CD26) or dipeptidyl peptidase-4 (DPP-4) emerged as a new receptor for entry of SARS-CoV-2. Therefore, DPP-4 inhibitors like sitagliptin could be effective in treating Covid-19. Hence, we aimed in the present critical review to assess the potential role of sitagliptin in Covid-19. DPP-4 inhibitors are effective against the increased severity of SARS-CoV-2 infections. Moreover, DPP-4 inhibitors inhibit the interaction between DPP-4 and scaffolding proteins which are essential for endosome formation and replication of SARS-CoV-2. Therefore, sitagliptin through attenuation of the inflammatory signaling pathway and augmentation of stromal-derived factor-1 (SDF-1) may decrease the pathogenesis of SARS-CoV-2 infection and could be a possible therapeutic modality in treating Covid-19 patients. In conclusion, the DPP-4 receptor is regarded as a potential receptor for the binding and entry of SARS-CoV-2. Inhibition of these receptors by the DPP-4 inhibitor, sitagliptin, can reduce the pathogenesis of the infection caused by SARS-CoV-2 and their associated activation of the inflammatory signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.